PATH Key Stats
- NUPATHE INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposi Yahoo 02/21 17:02 ET
- Teva Completes Tender Offer for NuPathe Inc. Shares Business Wire 02/21 09:15 ET
- Endo Health Scores Legal Victory - Analyst Blog Zacks 01/30 12:02 ET
- Special Situations Update: NuPathe Correction Seeking Alpha 01/29 05:57 ET
- The NuPathe Contingent Value Right: Paying 25 Cents For A Dollar Seeking Alpha 01/28 10:49 ET
- Special Situations Alert: Details Behind Why I Bought NuPathe Inc. Seeking Alpha 01/28 07:35 ET
- Wedbush Downgrades NuPathe (PATH) to Neutral Street Insider 01/22 12:43 ET
- Teva to Acquire NuPathe - Analyst Blog Zacks 01/22 10:58 ET
- Teva Expands CNS Specialty Business with Acquisition of NuPathe noodls 01/21 08:18 ET
- Teva to Acquire NuPathe for $144 Million, Outbidding Endo Bloomberg 01/21 07:50 ET
PATH Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). NuPathe is up 23.19% over the last year vs S&P 500 Total Return up 24.54%, Endo International up 138.0%, and Jazz Pharmaceuticals up 156.2%.
Balance Sheet View Statement
Pro Ratings for PATH
Pro Strategies Featuring PATH
Did NuPathe make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
- Sector: Healthcare
- Industry: Biotechnology
- Headquarters Country: United States
- Headquarters State/Province: Pennsylvania
- Incorporation Country: United States
- Incorporation State/Province: Delaware
NuPathe Inc., is a biopharmaceutical company that develops and commercializes branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders.